The new wave of immunotherapy antibodies in cancers and rare haematological diseases
A clinical stage immuno-oncology company that designs and develops a new generation of therapeutic antibodies
Welcome to ElsaLys Biotech
ELSALYS BIOTECH is an immuno-oncology company which designs and develops a new generation of therapeutic antibodies targeting tumors and their immune and/or vascular microenvironment.
Its mission is at the heart of personalised and precision medicine where the ultimate goal is to increase the proportion of responders to new treatments.
Today ELSALYS BIOTECH is conducting 4 proprietary development programs including Inolimomab (LEUKOTAC®), an immunotherapy antibody that has recently demonstrated its clinical superiority in Phase 3 in an orphan disease with very poor prognosis: steroid-resistant acute Graft-versus-Host Disease and that is currently benefitting of cohort ATU in France for the treatment of graft-versus-host disease, corticosteroid-resistant or corticosteroid-dependent, with grade II-IV.
The company is acting today in 3 main medical fields :